Tempus With Takeda Announces Expansion Of Collaboration To Leverage Multimodal Real-World Datasets And Biological Model Systems In Oncology Research And Development
Tempus With Takeda Announces Expansion Of Collaboration To Leverage Multimodal Real-World Datasets And Biological Model Systems In Oncology Research And Development
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts.
Tempus AI公司（納斯達克股票代碼：TEM），作爲一家領先採用人工智能推動精準醫療和患者護理發展的科技公司，今天宣佈擴大與武田（紐交所股票代碼：TAK）的合作，該合作以數據爲先導，旨在增強武田的腫瘤研發工作。
After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus' multimodal real-world datasets and Tempus' biological modeling capabilities to advance Takeda's pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, bispecifics and gamma delta T-cell therapies.
在最初利用Tempus的去標識化多模態數據集展開合作後，這項新協議將進一步拓展該項工作。武田將結合Tempus的多模態實際數據集和Tempus的生物建模能力，推進武田的癌症治療藥物管線，其中包括抗體藥物共軛物（ADCs）、小分子藥物、雙特異抗體和γδ T細胞療法。
Takeda researchers will use Tempus' analytics platform, Lens, to gain real-time access to de-identified patient records as well as a suite of AI-enabled tools to accelerate critical insights for Takeda's drug development efforts. Initial work has resulted in research that will be presented at an upcoming medical congress.
武田研究人員將使用Tempus的分析平台Lens，實時獲取去標識化患者記錄，並獲得一套人工智能工具，加速對武田藥物研發工作的關鍵見解。最初的工作已導致將在即將舉行的醫學大會上展示的研究成果。
譯文內容由第三人軟體翻譯。